EGAGenomicsIllumina HiSeq 2000Cancer Genomicshttps://ega-archive.org/studies/EGAS00001000648EGAEGA study EGAS00001000648FinHer Breast Cancer StudyEGArestrictedBreast Carcinoma, Human Mammary Neoplasm, primary breast cancer, Carcinoma, malignant tumor of the breast, Breast Carcinomas, "breast neoplasm" EXACT [MTH:120], Neoplasms, mammary neoplasm, Mammary Cancers, Human Mammary Neoplasms, Tumor, "breast tumor" EXACT [NCI2004_11_17:C2910], Human, Breast Malignant Neoplasm, Breast Malignant Tumor, "neoplasm of breast (disorder)" EXACT [SNOMEDCT_2005_07_31:126926005], Mammary Carcinomas, Breast Tumor, Neoplasm, Human Mammary Carcinoma, "mammary tumor" EXACT [CSP2005:2016-0671], NOS, breast tumor, cancer of the breast, Malignant Neoplasm of Breast, Carcinomas, BC, Mammary Neoplasms, malignant neoplasm of breast, Human Mammary, Breast Neoplasm, Mammary Neoplasm, Mammary Carcinoma, Human Mammary Carcinomas, study., Cancers, "mammary neoplasm" RELATED [], Cancer of the Breast, breast cancer, cancer of breast, Malignant Tumor of Breast, Mammary, Mammary Cancer, Breast Tumors, Breast Cancer, Breast Malignant Tumors, Cancer of Breast, Breast, mammary cancer, cancer, mammary tumor, Breast Malignant Neoplasms, breast, Tumors, Cancerprimary breast cancer, malignant tumor of the breast, Materials, Care Standards, Neoplasms, low frequency, Benign Neoplasm, number, mammary neoplasm, Gene, Mammary Cancers, Human Mammary Neoplasms, Tumor, Malignant, presence, Human, Relative, Breast Malignant Tumor, "neoplasm of breast (disorder)" EXACT [SNOMEDCT_2005_07_31:126926005], Breast Tumor, "mammary tumor" EXACT [CSP2005:2016-0671], breast tumor, cancer of the breast, HER2 Positive breast cancer, BC, treatment, study, Mammary Neoplasms, malignant neoplasm of breast, Human Mammary, Trastuzumab beta, ADIPSIN, Genetic, Malignancy, Mammary Neoplasm, Her2-receptor positive breast cancer, Mammary Carcinoma, Human Mammary Carcinomas, Cancer of the Breast, HER2 Overexpressing subtype of breast carcinoma, genetic, Neoplasias, malignant neoplasm, cancer of breast, Malignant Tumor of Breast, Mammary, Mammary Cancer, Clients, disease management, Therapies, Malignancies, Breast, mammary cancer, constitutitional genetic, mammary tumor, Breast Malignant Neoplasms, infrequent, Cancer, Tumors, Therapy, DF, Breast Carcinoma, Human Mammary Neoplasm, Carcinoma, Breast Carcinomas, ERBB2 Overexpressing subtype of breast carcinoma, Malignant Neoplasm, "breast neoplasm" EXACT [MTH:120], HER2 positive breast carcinoma, Adn, ADN, Trastuzumab qyyp, Arts, Herceptin, familial, Trazimera, "breast tumor" EXACT [NCI2004_11_17:C2910], Cistrons, Client, Breast Malignant Neoplasm, count in organism, MT, Benign, Mammary Carcinomas, Relative Risks, Neoplasm, sequence, Genetic Materials, Human Mammary Carcinoma, NOS, Standards of Care, Malignant Neoplasm of Breast, Genetic Material, Relative Risk, Trastuzumab, Carcinomas, primary cancer, Breast Neoplasm, Industrial, PFD., Industrial Arts, Risk, Risks, Benign Neoplasms, Cancers, "mammary neoplasm" RELATED [], HER2 Overexpressing breast carcinoma, malignant tumor, Treatments, primary structure of sequence macromolecule, beta, Malignant Neoplasms, Trastuzumab-qyyp, breast cancer, Patient, Therapeutic, Material, Breast Tumors, Breast Cancer, cardinality, Breast Malignant Tumors, Cistron, Cancer of Breast, Treatment, inherited genetic, cancer, hereditary, Neoplasia, Care Standard, breastfalseFinHer Breast Cancer StudyThe purpose of this study is to sequence 500 known cancer genes in 960 newly diagnosed high risk breast cancer patients treated with current standard of care therapies and trastuzumab, for somatic alteration and copy number changes. We will be using next gen sequencing technology to determine the prognostic relevance of these somatic genetic alterations and of teh low frequency events to determine if they are associated with trastuzumab benefit or HER2 positive breast cancer, i.e. treatment interaction. The samples will be analysed adn correlated with clinical variables including outcome.2017-07-26 15:39:25EGAS000010006489606EGAD00001000871EGAC00001000000